Clinical trial
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children…
NCT00090311 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00090311 |
|---|---|
| Title | Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania |
| Official title | A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated) |
| Acronym | ANCHOR 149 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | quetiapine fumarate |
| Enrollment | 220 |
| Start date | Jul 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Aug 30, 2004 |
| Last update posted | Jan 4, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: